CS Paper Radar

CoRe-WM: Conditioned Response-State World Modeling for Longitudinal Treatment-Response Prediction in Breast DCE-MRI

Lin Zhao, Bowen Chen, Qiaohui Gao, Shaowen Wan, Xiang Li, Wei Liu, Tianming Liu

cs.CV ·submitted 2026-10-18 15:25 UTC · v1

Abstract

Pathologic complete response (pCR) after neoadjuvant chemotherapy is a key prognostic indicator in aggressive breast cancer, yet existing prediction approaches either rely on pretreatment imaging alone, missing the patient's evolving response, or optimize multi-visit classifiers under direct outcome supervision, coupling representation learning with the clinical endpoint. We formulate longitudinal pCR prediction as a world-modeling problem and propose Conditioned Response-state World Modeling (CoRe-WM), which learns a latent state-transition model that predicts the next imaging state from the observed sequence. The transition function is conditioned on patient clinical profile and assigned therapy through additive shift and feature-wise modulation, enabling patient- and treatment-specific dynamics. A Factorized Response State pathway further decouples treatment-response dynamics from imaging appearance by encoding the structural prior that response manifests primarily in lesion morphology. After pretraining, all parameters are frozen and a linear readout predicts pCR at each clinical decision point. We evaluate CoRe-WM on I-SPY2 under five-fold cross-validation and assess cross-cohort transfer on I-SPY1. CoRe-WM achieves the highest discrimination among all evaluated methods at every prospective decision point, and demonstrates robust cross-cohort transfer. Ablation studies identify patient-profile conditioning and the factorized response pathway as the principal contributors. These results establish world-model-based representation learning as a promising framework for outcome prediction in oncology and beyond.

Closest papers

Nearest neighbours by meaning across the whole index.

Early Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy Using Temporal Deep Learning on DWI

cs.AI ·2026-08-18 ·Pablo García Marcos, Md. Tarequl Islam, Paula Puerta González, Guillermo Lorenzo, Héctor Gómez +3 more
similarity 0.76
Abstract

Early identification of non-responders to neoadjuvant chemotherapy (NACT) is crucial for timely treatment adaptation in breast cancer. However, many existing predictive models rely on multiparametric magnetic resonance imaging (MRI), late treatment time points, or extensive clinical data, which limits their applicability. This study proposes a deep learning framework for early prediction of pathological complete response (pCR) using only diffusion-weighted MRI (DW-MRI) acquired at baseline and after the first NACT cycle. This framework feeds cropped tumor-centered patches to an EfficientNet-based temporal model that directly learns tumor shape and local tissue characteristics without explicit radiomic feature engineering. The model, trained with 10-fold cross-validation, achieved an area under the receiver operating characteristic curve (AUC) of 0.90 for pCR prediction after one cycle, providing actionable information after a single treatment cycle while avoiding gadolinium administration and reducing dependence on heterogeneous clinical data. By focusing on the baseline-to-first-cycle window instead of later stages, the approach supports earlier escalation or de-escalation of NACT, and its exclusive reliance on DW-MRI facilitates protocol standardization, multi-centre deployment and privacy-preserving data sharing. These results demonstrate that DW-MRI-based deep learning on tumor-centered patches constitutes a minimally invasive, clinically deployable strategy for early pCR prediction, with direct implications for personalized treatment adaptation in neoadjuvant breast cancer therapy.

0.21

PerturbRx: Learning Treatment-Conditioned Latent Transitions for Patient Drug Response Prediction

cs.LG q-bio.QM ·2026-08-21 ·Yoshitaka Inoue, Minoh Jeong, Alfred Hero, Rui Kuang, Augustin Luna
similarity 0.73
Abstract

Scarce data and tumor heterogeneity limit patient-level cancer treatment-response prediction. Existing approaches predict response from pretreatment molecular profiles and drug representations, without explicitly modeling the molecular changes expected under treatment. We propose PerturbRx, a treatment-conditioned representation learning framework that learns intervention-induced latent transitions and uses them as patient-drug response features. PerturbRx trains a drug- and dose-conditioned transition predictor from context-matched but cell-unpaired control and treated single-cell populations, then freezes and transfers the predictor to pretreatment patient profiles without requiring post-treatment measurements. The transition is combined with patient and drug representations to predict response. Across TCGA and patient-derived xenograft benchmarks, PerturbRx achieves the strongest aggregate predictive performance among the evaluated methods. These results support perturbation-pretrained latent transitions as useful representations for patient-level drug-response prediction.

0.25

Neoadjuvant chemotherapy response prediction using pretreatment diffusion and contrast-enhanced magnetic resonance imaging with clinical variables

cs.AI cs.CV ·2026-08-18 ·Pablo García Marcos, Paula Puerta González, Guillermo Lorenzo, Héctor Gómez, Covadonga del Camino +4 more
similarity 0.70
Abstract

Prediction of pathological complete response before neoadjuvant chemotherapy may facilitate more tailored therapeutic planning for breast cancer patients. This work proposes a deep-learning model for pretreatment data only, combining apparent diffusion coefficient maps, dynamic contrast-enhanced magnetic resonance imaging, and clinical variables. The study uses the public ACRIN 6698/I-SPY2 multicenter dataset. The architecture employs EfficientNet-B0 pretrained encoders for image feature extraction and late fusion with clinical information. Multiple clinical variables were evaluated, including age, race, histological type, HR/HER2 subtype, SBR grade, and maximum diameter. Only HR/HER2 subtype improved the average area under the receiver operating characteristic curve (AUC) and was retained in the final model. Using stratified five-fold cross-validation, standalone apparent diffusion coefficient maps achieved a mean AUC of 0.79, whereas dynamic contrast-enhanced magnetic resonance imaging achieved 0.74. Adding HR/HER2 subtype improved performance to 0.83 and 0.81, respectively. The final configuration, using both imaging modalities and HR/HER2 subtype, achieved an AUC of 0.86. These results support pretreatment multimodal learning for response prediction, although external validation is required before clinical use.

0.27

Mammo-LIFE: Longitudinal Mammographic Imaging and Clinical Feature Enrichment for Post-Radiotherapy Outcome Prediction

cs.CV eess.IV ·2026-09-22 ·Farnoush Bayatmakou, Maryam Hosseini, Reza Taleei, Arash Mohammadi
similarity 0.70
Abstract

Recent advances in Artificial Intelligence (AI)-powered Computer-Aided Diagnosis (CAD) systems have substantially improved breast cancer screening, diagnosis, and prognosis. Comparatively, postradiotherapy outcome prediction using paired longitudinal mammograms has received considerably less attention. This is largely due to the limited availability of well-annotated longitudinal datasets. Longitudinal mammograms, coupled with paired pre- and post-treatment information, provide a unique opportunity to characterize treatment-induced breast tissue changes following radiotherapy. The resulting learned representations can serve as a valuable asset for advancing personalized radiotherapy planning and post-treatment management. In this context, we propose Mammo-LIFE, a patient-level multimodal framework for post-radiotherapy outcome prediction that combines longitudinal mammographic features with patient-level clinical variables. The imaging branch processes paired pre- and post-treatment mammograms acquired from the four standard views using a mammography-specific encoder adapted via Low-Rank Adaptation (LoRA). Within each view, preand post-treatment representations are explicitly compared through a longitudinal comparison module to capture treatment-related changes. The resulting view-level embeddings are then aggregated using learned view-attention pooling to form a unified patient-level mammographic representation. Selected clinical variables are subsequently combined with the image-derived prediction probability through a late-fusion strategy. To evaluate the effectiveness of combining paired longitudinal mammograms with clinical information, experiments were conducted on an in-house clinical cohort using patient-level stratified five-fold cross-validation.

0.26

Transcriptome-informed multi-modal AI for predicting neoadjuvant therapy response from breast cancer biopsies

cs.AI ·2026-10-02 ·Jungkyu Park, Dhruva Biswas, Joseph Cappadona, Cerise Tang, Ken G. Zeng +20 more
similarity 0.70
Abstract

Scarcity of labeled data limits development of deep learning biomarkers in oncology. We develop a two-stage AI model predicting pathological complete response (pCR) to neoadjuvant therapy in breast cancer. The first stage learns the transcriptome from histopathology using 8,742 patients across 32 cancer types, corroborated by pathologist review and spatial agreement with measured expression. This simplifies the second stage to predicting pCR from inferred expression and clinical variables. Developed using 1,080 patients (five cohorts) and evaluated in 1,412 patients (nine cohorts), the model achieves a pooled AUROC of 0.79 (95% CI, 0.73-0.85), discriminating responders within molecular subtypes. It outperforms histopathological biomarkers, remaining stable across intratumoral sampling and with minimal biopsy tissue. Ablations show transcriptome-wide inference improves discrimination over clinical variables alone or one-stage pathology models, and robustness by avoiding genomic assays' gene selection constraints. These results indicate that biologically informed compression may generalize to data-sparse applications in precision oncology.

0.06

CaMeWM: A Causal Medical World Model for Generative Tumor Evolution and Treatment Planning

cs.CV cs.LG ·2026-10-17 ·Huanlong Gao, Xuelei He, Fengjun Zhao, Xiaowei He
similarity 0.69
Abstract · 30 pages,8 figures,12 tables,including supplementary material

Treatment planning is intrinsically counterfactual: clinicians must compare how a patient's tumor and survival would evolve under competing regimens, whereas a retrospective cohort records only the regimen received and one follow-up scan. A treatment-conditioned generator trained on such data can therefore reproduce historical treatment allocation rather than simulate the interventional disease dynamics needed to rank regimens. We introduce \textbf{CaMeWM}, a causal medical world model for supported post-TACE tumor evolution and treatment planning. CaMeWM implements one intervention-to-decision loop rather than three independent prediction tasks: it first admits a queried regimen only for clinically comparable histories with empirical treatment support; it then generates a distribution of lesion-local follow-up worlds through an action-conditioned response descriptor, deterministic anchor, and residual 3D diffusion transition; and it finally maps sampled worlds to restricted mean survival time (RMST) with a response-Cox utility model. Under pre-treatment adjustment and positivity, this loop estimates a prespecified, support-restricted g-formula target; all selection and nuisance estimation are fold-local, and the induced policy is evaluated by cross-fitted, censoring-adjusted doubly robust estimation. Across 79 paired out-of-fold episodes, CaMeWM achieves 0.618 SSIM and 0.528 change-map SSIM for follow-up CT transition, while its generated-world survival pathway attains a 0.615 C-index; factual-only AIPW estimates a 9.60-week RMST gain (95\% CI 0.61--18.13) for the frozen policy. CaMeWM provides an inspectable basis for retrospective, support-restricted treatment planning.

0.33

Feature Space Guidance for Breast Cancer Classification in DCE-MRI

cs.CV cs.AI ·2026-09-26 ·Benjamin Hamm, Yannick Kirchhoff, Maximilian Rokuss, Moritz Langenberg, Constantin Ulrich +4 more
top venuecode/data similarity 0.66
Abstract · 11 pages, 2 figures, 2 tables. Code: https://github.com/MIC-DKFZ/CURIAtor

Dynamic contrast enhanced breast MRI (DCE-MRI) is a powerful clinical tool for breast cancer detection, providing high resolution anatomical detail together with rich temporal contrast information. However, high dimensional 4D inputs, small lesions, and heterogeneous acquisition protocols across clinical sites hinder robust automated classification of healthy, benign, and malignant cases. To address these challenges, we propose a framework that dynamically analyzes latent representations to adapt to protocol-specific characteristics. Spatial variability is mitigated by reducing confounding background uptake and compensating for misalignment caused by deformable soft tissue. Additionally, relationships in the latent space across phases are leveraged to select the most informative temporal features, improving robustness to protocol-specific temporal variability. Finally, task specific discriminative features are promoted through large scale supervised lesion segmentation pretraining, which substantially enhances downstream finetuning. Evaluated under leave-one-center-out validation on the ODELIA dataset and the held-out AMBL cohort, the proposed framework substantially outperforms finetuned radiology foundation models and prior methods, improving mean AUROC by nearly 8 points and balanced accuracy by 4 points over the strongest baseline. Additionally, our method achieved first place in the MICCAI ODELIA Breast MRI Challenge 2025, further demonstrating its effectiveness for robust breast cancer classification. We publicly release our codebase under https://github.com/MIC-DKFZ/CURIAtor.

0.70

HiSTOR: Structured Treatment-outcome Representation Learning for High-Dimensional Longitudinal Data

cs.LG cs.AI ·2026-10-13 ·Chuanqi Lao, Junzhou Huang, Qiao Liu
similarity 0.65
Abstract

Estimating potential outcomes under alternative treatment sequences is essential for personalized decision-making, but remains challenging with high-dimensional covariates and time-varying confounding. In this study, we propose HiSTOR (High-dimensional Structured Treatment-Outcome Representation), an end-to-end framework that integrates nonlinear dimension reduction with longitudinal counterfactual prediction. The central idea is to learn structured low-dimensional representations of both current patient states and evolving histories, according to their shared and distinct relationships with treatment assignment and outcomes. This extends latent-space covariate adjustment to longitudinal settings, jointly addressing covariate dimensionality and historical complexity. The resulting framework supports one-step and multi-step outcome prediction under specified treatment sequences. Experiments on CVSim and CancerSim demonstrate the superiority of HiSTOR across varying covariate dimensions, confounding strengths, and prediction horizons compared to state-of-the-art methods. To sum up, HiSTOR offers a unified approach to connecting high-dimensional covariate adjustment with longitudinal potential-outcome prediction.

0.18